bluebird bio, Inc. (BLUE)
NASDAQ: BLUE · IEX Real-Time Price · USD
0.923
-0.052 (-5.35%)
At close: Jul 2, 2024, 4:00 PM
0.933
+0.010 (1.06%)
After-hours: Jul 2, 2024, 7:47 PM EDT
bluebird bio Revenue
bluebird bio had revenue of $21.73M in the twelve months ending September 30, 2023, with 322.60% growth year-over-year. Revenue in the quarter ending September 30, 2023 was $12.39M with 17,353.52% year-over-year growth. In the year 2022, bluebird bio had annual revenue of $3.60M, a decrease of -1.77%.
Revenue (ttm)
$21.73M
Revenue Growth
+322.60%
P/S Ratio
8.19
Revenue / Employee
$67,263
Employees
323
Market Cap
177.92M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2022 | 3.60M | -65.00K | -1.77% |
Dec 31, 2021 | 3.66M | - | - |
Dec 31, 2020 | 0 | - | - |
Dec 31, 2019 | 0 | - | - |
Dec 31, 2018 | 54.58M | 19.15M | 54.06% |
Dec 31, 2017 | 35.43M | 29.27M | 475.58% |
Dec 31, 2016 | 6.16M | -7.92M | -56.28% |
Dec 31, 2015 | 14.08M | -11.34M | -44.62% |
Dec 31, 2014 | 25.42M | 5.24M | 25.97% |
Dec 31, 2013 | 20.18M | 19.84M | 5,835.59% |
Dec 31, 2012 | 340.00K | -542.00K | -61.45% |
Dec 31, 2011 | 882.00K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionBLUE News
- 5 days ago - BLUE ALERT: Bragar Eagel & Squire, P.C. is Investigating Bluebird bio Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm - GlobeNewsWire
- 4 weeks ago - 2Flo Ventures Announces Addition of Renowned Life Sciences Executive Charlotte Jones-Burton, MD, MS as a Partner - PRNewsWire
- 4 weeks ago - Bluebird bio appoints new CFO to oversee financial restatements - Reuters
- 4 weeks ago - bluebird bio Appoints O. James Sterling as Chief Financial Officer - Business Wire
- 5 weeks ago - The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against bluebird bio, Inc. (BLUE) - Business Wire
- 5 weeks ago - Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of May 28, 2024 in bluebird bio Lawsuit - BLUE - PRNewsWire
- 5 weeks ago - SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against bluebird bio, Inc. - BLUE - PRNewsWire
- 5 weeks ago - BLUE Investors Have Opportunity to Lead bluebird bio, Inc. Securities Fraud Lawsuit - PRNewsWire